American Trust Makes New $600,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

American Trust bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 571 shares of the biopharmaceutical company’s stock, valued at approximately $600,000.

A number of other institutional investors have also modified their holdings of REGN. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after acquiring an additional 96,266 shares in the last quarter. TD Asset Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after acquiring an additional 82,034 shares during the period. Finally, Icon Wealth Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Citigroup started coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price target on the stock. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Leerink Partners restated a “market perform” rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,099.90.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $731.30 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $728.68 and a fifty-two week high of $1,211.20. The company has a market capitalization of $80.36 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 2.32 and a beta of 0.08. The stock has a fifty day moving average of $849.77 and a two-hundred day moving average of $1,003.80. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.